Zentalis Pharmaceuticals Inc (ZNTL)


Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Zentalis Pharmaceuticals Inc chart...

About the Company

developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer

CEO

Kimberly Lynn Blackwell

Exchange

NASDAQ

Website

zentalis.com

$0M

Total Revenue

166

Employees

$981M

Market Capitalization

-3.07

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ZNTL News

What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock

1mon ago, source: Hosted on MSN

Earnings Estimate Revisions for Zentalis Pharmaceuticals, Inc. This company is expected to earn -$4.49 per share for the fiscal year ending December 2023, which represents a year-over-year change ...

Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet

20d ago, source: Yahoo Finance

Zentalis Pharmaceuticals, Inc. (ZNTL) closed the last trading session at $14.71, gaining 21.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price ...

Zentalis Pharmaceuticals Inc Ordinary Shares

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Zentalis Pharmaceuticals Inc (ZNTL) Reports Full Year 2023 Financial Results and Provides ...

20d ago, source: Yahoo Finance

Warning! GuruFocus has detected 2 Warning Sign with ZNTL. Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) released its 8-K filing on February 27, 2024, detailing the company's financial results for the ...

Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates

2mon ago, source: Nasdaq

NEW YORK and SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically ...

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

17d ago, source: Business Insider

NEW YORK & SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically ...

Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates

21d ago, source: Business Insider

Corporate Updates Anticipated Upcoming Milestones Full Year 2023 Financial Results About Azenosertib Zentalis ® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company discovering and ...

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

18d ago, source: Stockhouse

NEW YORK & SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically ...

Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates

2mon ago, source: Stockhouse

NEW YORK and SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...